We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Transgenomic Announces Contract with OSI Pharmaceuticals for Cancer Genetic Analysis
News

Transgenomic Announces Contract with OSI Pharmaceuticals for Cancer Genetic Analysis

Transgenomic Announces Contract with OSI Pharmaceuticals for Cancer Genetic Analysis
News

Transgenomic Announces Contract with OSI Pharmaceuticals for Cancer Genetic Analysis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Transgenomic Announces Contract with OSI Pharmaceuticals for Cancer Genetic Analysis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Transgenomic, Inc. has announced that the Company previously signed a contract with OSI Pharmaceuticals, Inc. to complete an analysis of specific cancer pathway genes.

According to Company, it has developed a high throughput, high sensitivity methodology for characterizing genetic variants implicated in malignant neoplasia. Through the development and use of high throughput genome scanning with proprietary endonucleases, forward and reverse Sanger sequencing, and unparalleled variant annotation, Transgenomic can reliably detect pathogenic genetic mutations.

In making the announcement, Transgenomic's President and Chief Executive Officer, Craig Tuttle, stated, "The contract with OSI Pharmaceuticals enables Transgenomic to utilize its highly developed expertise in genetic variant detection to assist OSI Pharmaceuticals, Inc. in its development efforts. This contract follows genetic analysis work done with other pharmaceutical companies. It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients."

Advertisement